Stocktoria
IDEAYA Biosciences, Inc. IDYA
IDEAYA Biosciences, Inc. (IDYA) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $218.7M at a -52.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-12 | Wedbush | Outperform (reit) |
| 2026-06-02 | Wedbush | Outperform (reit) |
| 2026-05-07 | Mizuho | Outperform (main) |
| 2026-04-14 | Goldman Sachs | Neutral (main) |
| 2026-04-14 | Wells Fargo | Overweight (main) |
| 2026-04-14 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.548 |
| Retained earnings / assets | -0.664 |
| EBIT / assets | -0.144 |
| Equity / liabilities | 11.841 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IDYA | IDEAYA Biosciences, Inc. | 3/9 | 12.9 | — | — |
| VNDA | Vanda Pharmaceuticals Inc. | 2/9 | 0.13 | — | +8.7% |
| AMRN | AMARIN CORP PLCUK | 5/9 | -2.07 | — | -6.5% |
| PBYI | PUMA BIOTECHNOLOGY, INC. | 6/9 | -14.13 | 13.3 | -0.9% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
FAQ
Is IDYA financially healthy?
IDEAYA Biosciences, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does IDYA pay a dividend?
No, IDEAYA Biosciences, Inc. does not currently pay a dividend.
How profitable is IDYA?
In FY2025, IDEAYA Biosciences, Inc. had a net margin of -52.0% and a return on equity of -11.1%.
What is the analyst price target for IDYA?
The average Wall-Street price target for IDEAYA Biosciences, Inc. is $52.79, about 42.8% above the recent price, from 14 analysts.
Is IDYA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on IDEAYA Biosciences, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.